Ernexa Therapeutics Inc. — Director's Dealing 2021

Sep 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-09-20

Reporting Person: Sidhu Roger (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-20	Stock Option	$9.96	A	161300	Acquired	2031-09-20	Common Stock (161300)	Direct
2021-09-20	Restricted Stock Unit	$	A	80650	Acquired	2031-09-20	Common Stock (80650)	Direct

Footnotes

F1: The option vests and becomes exercisable over four years, with twenty-five percent of the shares covered thereby vesting on September 20, 2022, and 1/36 of the remaining shares covered thereby vesting on the twentieth day of each calendar month from October 2022 through September 20, 2025, subject to continued service through each vesting date.

F2: Each restricted stock unit represents a contingent right to receive one share of common stock.

F3: The RSU Grant vests and becomes exercisable in four equal installments on September 20 of each of 2022, 2023, 2024 and 2025, provided that it shall vest in full immediately prior to a change in control (as defined in Dr. Sidhu's Executive Employment Agreement, effective September 20, 2021), subject to continued service through each vesting date.